GLP-1 Medications: Long-Term Effects on Metabolic Health

What actually happens to your body after months or years on GLP-1 medication? It is a fair question. Most articles about Ozempic or Wegovy focus on the first few months of weight loss, but the long-term metabolic picture tells a different story.

The short answer: semaglutide and tirzepatide do more than help you lose weight. Data from trials running two to four years shows improvements in cardiovascular risk, blood sugar regulation, blood pressure, and cholesterol. The SELECT trial, which followed over 17,000 patients for four years on semaglutide 2.4mg, found a 20% reduction in major adverse cardiovascular events.

But the long-term picture is not all positive. Lean muscle loss, potential nutrient gaps, and the question of what happens when you stop treatment all deserve honest answers. This article covers the evidence on both sides, so you can have a better conversation with your doctor about what long-term GLP-1 treatment means for your metabolic health.

Cardiovascular benefits: what the SELECT trial showed

The strongest long-term data on GLP-1 medications and heart health comes from the SELECT trial, published in the New England Journal of Medicine in 2023. Here is what they found.

The study: 17,604 adults aged 45 and older with pre-existing cardiovascular disease but no diabetes. They took semaglutide 2.4mg weekly (the same dose as Wegovy) or placebo for a median of 40 months.

The results:
- 20% reduction in major adverse cardiovascular events (heart attack, stroke, or cardiovascular death)
- 10.2% average weight loss sustained over four years, compared to 1.5% with placebo
- Waist circumference reduced by 7.7cm vs 1.3cm with placebo
- Systolic blood pressure dropped by about 4.8 mmHg, diastolic by 2.5 mmHg

These are not small numbers. A 20% reduction in cardiovascular events is comparable to what statins achieve, and SELECT is the first trial to show this benefit in a population without diabetes.

For context, an earlier trial called LEADER tested liraglutide 1.8mg (a lower dose than the weight loss dose) in patients with type 2 diabetes and found a 13% reduction in cardiovascular events over 3.8 years. The SELECT results suggest the cardiovascular benefits extend beyond diabetic populations.

What this means in practical terms: if you are taking semaglutide for weight loss and you also have risk factors like high blood pressure, high cholesterol, or a family history of heart disease, the medication may be doing more for your heart health than you realise.

Blood sugar and metabolic improvements

Even if you do not have diabetes, GLP-1 medications improve how your body handles glucose. This matters because insulin resistance often develops silently for years before it becomes type 2 diabetes.

For people without diabetes:
GLP-1 medications help maintain normal blood sugar by reducing fasting plasma glucose and fasting insulin levels. Because semaglutide and tirzepatide work in a glucose-dependent way (they stimulate insulin secretion only when blood sugar is elevated), the risk of hypoglycaemia is extremely low in non-diabetic patients. In the SELECT trial, 12% of participants moved from overweight or obese into the healthy BMI range within two years.

For people with type 2 diabetes:
The benefits are more pronounced but also more complex. In the STEP 2 trial, semaglutide 2.4mg produced a 9.6% weight loss and meaningful HbA1c reductions in patients with T2D over 68 weeks. Longer-term data shows HbA1c improvements of 0.4-1.7% compared to placebo, with the greatest reductions appearing within the first 12-18 weeks.

Beyond blood sugar, GLP-1 medications also improve:
- Triglycerides: reduced by 20-25% (SURMOUNT-1 data for tirzepatide)
- LDL cholesterol: modest reductions across trials
- Blood pressure: systolic reductions of 2-5 mmHg
- Resting heart rate: small sustained increase of 2-3 beats per minute (a known side effect, not considered dangerous)

These metabolic improvements are sustained as long as you continue treatment. But what happens when you stop?

Body composition: the muscle loss question

Weight loss on GLP-1 medications is not all fat. In the STEP 1 trial, lean mass accounted for about 25-40% of total weight loss. The SURMOUNT-1 trial with tirzepatide showed similar figures, with muscle loss making up roughly 25% of total weight reduction.

This is not unique to GLP-1 medications. Any significant weight loss, whether from dieting, bariatric surgery, or medication, involves some lean mass loss. The ratio is roughly consistent across methods. What matters is whether you take steps to minimise it.

Two things that help:
1. Protein intake of 80-120g daily (or 1.2-2.0g per kg of body weight). Spread across meals, not loaded into one sitting. If your appetite is very suppressed, a protein shake can bridge the gap.
2. Resistance training 2-3 times per week. Squats, lunges, push-ups, or resistance bands. The goal is to give your muscles a reason to stay.

A meta-analysis of GLP-1 trials lasting at least 52 weeks found no significant difference in bone fracture risk between medication and placebo groups. So while muscle loss is a real concern, bone health appears to hold up during treatment.

Nutrient gaps to watch for:
Reduced appetite means reduced food intake, which can lead to deficiencies over time. The most commonly reported are vitamin B12, vitamin D, folate, magnesium, and iron. Your doctor should monitor these through regular blood tests, especially if you are on treatment for more than six months.

What happens when you stop GLP-1 medication

This is the question that does not get enough attention. The STEP 4 trial tested exactly this: patients who had been on semaglutide for 20 weeks were either continued on the medication or switched to placebo.

Those switched to placebo regained about two-thirds of the weight they had lost within 48 weeks. Along with the weight regain, improvements in blood pressure, HbA1c, and lipid profiles also reversed.

The STEP 1 extension data (Wilding et al., 2022) confirmed this pattern. After stopping semaglutide, participants regained most of their lost weight over the following year.

What does this mean for you?

It does not mean you need to stay on GLP-1 medication forever, but it does mean that stopping abruptly without a plan is risky. The approach that works best:

• Build strong nutrition and exercise habits during treatment (see our guide on building habits while using GLP-1 medications)
• Taper gradually under doctor supervision rather than stopping cold
• Continue monitoring your weight and metabolic markers after stopping
• Restart treatment if weight regain exceeds 5% or metabolic markers deteriorate

Your doctor can help you decide whether long-term treatment, gradual tapering, or intermittent use is the right approach for your situation.

Maximising long-term metabolic benefits

If you want the best long-term outcomes from GLP-1 treatment, the evidence points to a few things that matter:

1. Combine medication with lifestyle changes from the start.
The STEP 3 trial showed that semaglutide combined with intensive behavioural therapy produced 16% weight loss at 68 weeks. The medication creates a window of reduced appetite; the habits you build during that window determine whether the benefits last.

2. Prioritise resistance training over cardio.
Both help, but resistance training directly addresses the muscle loss concern. Aim for 2-3 sessions per week, plus 150 minutes of moderate aerobic activity (walking, swimming, cycling). In Singapore, walking is practical year-round and costs nothing.

3. Monitor metabolic markers, not just weight.
Weight is one number. Your doctor should also be tracking blood pressure, fasting glucose or HbA1c, lipid panel, and kidney function at regular intervals. These markers tell a fuller story about your metabolic health than the scale alone.

How Trimly supports long-term GLP-1 treatment

Long-term treatment requires long-term monitoring. Trimly's doctor-led telehealth model is built for ongoing care, not one-off prescriptions.

• Video consultations with licensed Singapore doctors who understand the metabolic effects of semaglutide and tirzepatide, and can adjust your treatment plan as your body responds over months and years.
• Unlimited free follow-ups for the duration of your treatment. Dose adjustments, side effect management, and metabolic check-ins are all included.
• Medication delivered to your door, with no clinic visits required.
• WhatsApp support between consultations for quick questions about symptoms, diet, or exercise.

Treatment plans range from $350 to $650 per month, covering consultation, medication, delivery, and all follow-ups. Because Trimly focuses exclusively on GLP-1 weight loss treatment, your doctor tracks the specific metabolic markers and milestones that matter.

Frequently asked questions

Are GLP-1 medications safe to take long term?

The longest controlled trial data we have is the SELECT trial, which ran for four years with semaglutide 2.4mg. It showed sustained benefits and no new safety signals compared to shorter trials. The most common side effects remain gastrointestinal (nausea, constipation, diarrhoea), which typically improve within the first 4-8 weeks. Serious side effects like pancreatitis remain rare. Your doctor should monitor you regularly, especially for lean mass loss and potential nutrient deficiencies.

Do the cardiovascular benefits of GLP-1 medications apply to everyone?

The SELECT trial demonstrated cardiovascular benefits specifically in patients with pre-existing cardiovascular disease but without diabetes. The LEADER trial showed similar benefits in patients with type 2 diabetes. If you are taking GLP-1 medication purely for weight loss without cardiovascular risk factors, the direct cardiovascular benefit is less established, but the weight loss and metabolic improvements themselves reduce your overall risk profile.

What metabolic markers should I track while on GLP-1 treatment?

Beyond weight, ask your doctor to monitor: fasting glucose or HbA1c (even if you are not diabetic), blood pressure, lipid panel (LDL, HDL, triglycerides), kidney function, vitamin B12, and vitamin D. These markers give a clearer picture of your metabolic health than weight alone and help your doctor adjust your treatment over time.

Can I take GLP-1 medication intermittently rather than continuously?

Some doctors are exploring intermittent or cyclical dosing, where patients take GLP-1 medication for a period, stop, and restart if weight regain occurs. There is limited trial data on this approach so far, but it may be appropriate for some patients. Discuss this with your doctor, who can help weigh the pros and cons based on your metabolic profile and weight history.

Key takeaways

GLP-1 medications do more than reduce weight. Over two to four years, the evidence shows improvements in cardiovascular risk, blood sugar regulation, blood pressure, and cholesterol. The trade-offs, including lean mass loss, potential nutrient gaps, and weight regain after stopping, are manageable with the right approach: adequate protein, resistance training, and regular medical monitoring.

The most important thing is having a doctor who understands the long-term metabolic picture and can adjust your treatment accordingly. Weight loss is the most visible effect. The changes in blood pressure, blood sugar, and cholesterol may matter more in the long run.